342 filings
Page 5 of 18
8-K
l7yl7v0g
17 Jul 13
ARIAD Names Sarah J. Schlesinger, M.D. of Rockefeller University to Its Board of Directors
12:00am
8-K
2lcxyl78a2sy2t 283l
2 Jul 13
ARIAD Announces Marketing Authorization for Iclusig® (ponatinib) in the European Union
12:00am
8-K
nadxhycjud
24 Jun 13
Submission of Matters to a Vote of Security Holders
12:00am
8-K
uz7oks181now
4 Jun 13
Other Events
12:00am
8-K
ea59y191aii16u
7 May 13
ARIAD Reports First Quarter 2013 Financial Results and Development Progress
12:00am
8-K
37jmfqm9fcimktw3
25 Mar 13
ARIAD Announces That Iclusig™ (Ponatinib) Receives Positive CHMP Opinion for Approval in the European Union
12:00am
8-K
z5tgigb078 ioj0
14 Mar 13
Other Events
12:00am
8-K
dmvla ttb
25 Feb 13
ARIAD Reports 2012 Financial Results and Outlines Key Objectives for 2013
12:00am
8-K
mgwcosfo
29 Jan 13
ARIAD Announces Completion of Public Offering
12:00am
8-K
k5wvi3xj c06
24 Jan 13
ARIAD Announces Pricing of Public Offering of Common Stock
12:00am
8-K
hw03d
8 Jan 13
Entry into a Material Definitive Agreement
12:00am
8-K
26g204d1
8 Jan 13
Other Events
12:00am
8-K
a823h1aob0
17 Dec 12
Other Events
12:00am
8-K
0fhpb
11 Dec 12
ARIAD Announces 12-Month Data from Pivotal PACE Trial of Ponatinib in Heavily Pretreated Chronic-Phase CML Patients
12:00am
8-K
cui 18ts9u5sho79z64i
7 Nov 12
ARIAD Reports Third Quarter 2012 Financial Results and Development Progress
12:00am
8-K
x65faf srv
24 Oct 12
ARIAD Announces U.S. Food and Drug Administration Acceptance of NDA Filing for Ponatinib
12:00am
8-K
2k5mldpd47i
1 Oct 12
ARIAD Presents Initial Clinical Proof-of-Concept of AP26113 in Patients with Non-Small Cell Lung Cancer at ESMO 2012 Congress
12:00am
8-K
rkbzhemguj
19 Sep 12
MolecularMD and ARIAD Announce Voluntary Withdrawal Of MolecularMD’s Premarket Approval Application For BCR-ABL T315I Mutation Test
12:00am
8-K
qoupbx o3f11efjq
30 Aug 12
ARIAD Announces Submission of Marketing Authorization Application for Ponatinib to the European Medicines Agency
12:00am
8-K
hgr k50bezpy52
2 Aug 12
ARIAD Reports Second Quarter 2012 Financial Results and Development Progress
12:00am